Literature DB >> 27886856

A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease.

Masaki Okamoto1, Kiminori Fujimoto2, Junko Sadohara3, Kiyomi Furuya4, Shinjiro Kaieda5, Tomoya Miyamura6, Eiichi Suematsu7, Yasuhiko Kitasato8, Tomotaka Kawayama9, Hiroaki Ida10, Masao Ichiki11, Tomoaki Hoshino12.   

Abstract

BACKGROUND: The relationship between the histological pattern and survival in systemic sclerosis-associated interstitial lung disease (SSc-ILD) is unclear. In patients with SSc-ILD, we investigated whether the clinical data obtained by non-invasive examinations could be used for prognostic evaluation, and attempted to clarify whether complicating acute exacerbation (AE) and the selection of pharmacological therapy were associated with survival.
METHODS: Thirty-five patients with SSc-ILD, who had not been diagnosed by surgical lung biopsy were analyzed, retrospectively. The HRCT findings were evaluated by 2 radiologists and classified into "CT-UIP" or "CT-inconsistent with UIP" patterns based on whole lung interpretations. HRCT scores were calculated based on the extent of abnormality evidenced by HRCT. The log-rank test was used to determine variables, including clinical parameters and histories.
RESULTS: Twelve (34%) of the 35 patients died during a median follow-up period of approximately 7.9 years. The log-rank test showed that a higher mortality was associated with higher age, a CT-UIP pattern, a higher score for ground-glass attenuation with traction bronchiectasis on HRCT, and complicating AE, whereas a lower mortality was significantly associated with the use of immunosuppressants. A CT-UIP pattern was significantly associated with a higher incidence of later AE.
CONCLUSION: Treatment with immunosuppressants was associated with a longer survival, and complicating AE is a predictor of shortened survival in SSc-ILD patients. Among the clinical parameters determined by non-invasive examinations, a CT-UIP pattern and the extent of fibrotic lesions on HRCT, but not a histological pattern of UIP, may be predictors of shortened survival. Copyright Â
© 2016 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute exacerbation; Computed tomography; Immunosuppressant; Interstitial lung disease; Systemic sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27886856     DOI: 10.1016/j.resinv.2016.05.004

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  6 in total

1.  A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

Review 2.  Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.

Authors:  Małgorzata Chowaniec; Marta Skoczyńska; Renata Sokolik; Piotr Wiland
Journal:  Reumatologia       Date:  2018-08-31

3.  Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases.

Authors:  Johanna Salonen; Hannu Vähänikkilä; Minna Purokivi; Riitta Kaarteenaho
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

4.  Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-Interstitial Lung Disease: A Systematic Review.

Authors:  Nicholas Landini; Martina Orlandi; Cosimo Bruni; Edoardo Carlesi; Cosimo Nardi; Linda Calistri; Giovanni Morana; Sara Tomassetti; Stefano Colagrande; Marco Matucci-Cerinic
Journal:  Front Med (Lausanne)       Date:  2022-01-27

Review 5.  Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies.

Authors:  Sakir Ahmed; Sarit Sekhar Pattanaik; Mohit Kumar Rai; Alok Nath; Vikas Agarwal
Journal:  Mediterr J Rheumatol       Date:  2018-09-27

6.  Spontaneous Pneumo-Mediastinum in a Post-COVID-19 Patient with Systemic Sclerosis.

Authors:  Ilaria Mormile; Mauro Mormile; Gaetano Rea; Angelica Petraroli; Vittoria Barbieri; Amato de Paulis; Francesca Wanda Rossi
Journal:  Healthcare (Basel)       Date:  2022-03-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.